You have been chosen to receive this valuable information.
ACT Logo
 
 
Live Webinar Tuesday, June 26 at 12pm EDT
High-efficacy Subgroups in Clinical Trials: Why They Matter and How to Find Them
Presented by Garrick Wallstrom, PhD, Principal Research Biostatistician at SDC
 

Event Overview

In many clinical trials, we seek to identify a subgroup of patients in which an active treatment is most effective compared to a control. These high-efficacy subgroups may influence the enrollment criteria for future clinical trials and can change the clinical development strategy for the program.  Common strategies for finding these high-efficacy patient subgroups regularly find overly complex subgroups that are impractical for driving future trials and generate excessive false positive groups that fail to replicate in future trials.  SDC has developed and tested a novel strategy that identifies practical high-efficacy subgroups while controlling the Type 1 (false positive) error rate. Join this webinar to learn about SDC’s Constrained Search and Permutation Evaluation (CSPE) method for identifying high-efficacy subgroups in clinical trials, and how it can help optimize your clinical development strategy. 

Key Learning Objectives

  • What are high-efficacy subgroups in clinical trials and why they matter
  • What current methods are used to identify them, and pitfalls thereof
  • How the CSPE method identifies practical high-efficacy subgroups
  • How identifying these subgroups can optimize your clinical development strategy

Who Should Attend

Clinical trial professionals who seek to optimize their clinical development strategy

Can't Attend as Scheduled? 

All registrants will receive a link to view the presentation after the live event. Register now to view it on-demand later.

 
Forward to a Friend
    
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Applied Clinical Trails, a UBM publication. You are on the mailing list as %%emailaddress%%.